A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 96
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : LCSCs
Long Form : liver cancer stem cells
No. Year Title Co-occurring Abbreviation
2020 A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM-/CD133- nonStem Cells into EpCAM+/CD133+ Liver Cancer Stem Cells in HCC Cell Line HuH7. CSCs, HCC
2020 A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells. ---
2020 Aquaporin-9, Mediated by IGF2, Suppresses Liver Cancer Stem Cell Properties via Augmenting ROS/beta-Catenin/FOXO3a Signaling. AQP9, HCC, IGF2, IP, ROS
2020 BNIP3L-Dependent Mitophagy Promotes HBx-Induced Cancer Stemness of Hepatocellular Carcinoma Cells via Glycolysis Metabolism Reprogramming. HBV, HBx, HCC
2020 CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. 5-FU, CCND1, HCC
2020 CCND1 silencing suppresses liver cancer stem cell differentiation through inhibiting autophagy. CCND1, HCC
2020 Effect of SIRT1 activators and inhibitors on CD44+/CD133+‑enriched non‑small cell lung cancer cells. SIRT1
2020 Glioma-associated oncogene homolog 1 stimulates FOXP3 to promote non-small cell lung cancer stemness. GLI1, NSCLC
2020 Increased Oxidative Phosphorylation Is Required for Stemness Maintenance in Liver Cancer Stem Cells from Hepatocellular Carcinoma Cell Line HCCLM3 Cells. 2-DG, CSCs, OXPHOS
10  2020 Molecular mechanism of aquapontin (AQP3) in regulating differentiation and apoptosis of lung cancer stem cells through Wnt/GSK-3beta/beta-Catenin pathway. APC, AQP3, GSK-3beta, STAT3
11  2020 Salinomycin suppresses tumorigenicity of liver cancer stem cells and Wnt/beta-catenin signaling. CSCs
12  2020 Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2. ALDH2, EMT
13  2020 The DNMT1/miR-34a/FOXM1 Axis Contributes to Stemness of Liver Cancer Cells. DNMT1
14  2020 ZBP-89 negatively regulates self-renewal of liver cancer stem cells via suppression of Notch1 signaling pathway. HCC, NICD1
15  2019 A versatile polyion complex can intelligently respond to a tumor microenvironment to eliminate tumor stem cells for enhanced lung cancer targeted therapy. miR-31, PTK7, TD
16  2019 Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133+ HCC. ActD, AFP, CD, CSCs, HCC, HTS, ROS
17  2019 Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy. CAFs, CM, CQ, HCC
18  2019 Correlating tumor-infiltrating lymphocytes and lung cancer stem cells: a cross-sectional study. ALDH, FACS, NSCLC, TILs
19  2019 Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative-nitrosative stress signals. CSCs, Cygb, HCC, ONS
20  2019 Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells. DNMT, HCC, lncRNAs
21  2019 Enhanced anticancer effect of oncostatin M combined with salinomycin in CD133+ HepG2 liver cancer cells. AFP, ALB, OSM, SAL
22  2019 Long non-coding RNA MEG3 regulates migration and invasion of lung cancer stem cells via miR-650/SLC34A2 axis. FACS, LCCs, MEG3, NSCLC, OCT4, SLC34A2
23  2019 Low-level shear stress induces differentiation of liver cancer stem cells via the Wnt/beta-catenin signalling pathway. AFM
24  2019 Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. HCC, LFNG
25  2019 Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN. CSCs, LC, PTEN, qRT-PCR, TRAIL
26  2019 Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma. HCC
27  2019 Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4alpha. A1AT, AcLDL, H4R3me2s, PAS, PRMT5, SA-beta-gal
28  2018 Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles. ABC, CSCs, DOX, ELC, HepG2-TS, NDEs, NDs, NEs
29  2018 Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway. mTOR, PI3K
30  2018 Differentiation-inducing therapeutic effect of Notch inhibition in reversing malignant transformation of liver normal stem cells via MET. HOTAIR, ICG, LNSCs, MET
31  2018 Effect of Bmi-1-mediated NF-kappaB signaling pathway on the stem-like properties of CD133+ human liver cancer cells. ---
32  2018 Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis. IGF1
33  2018 High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma. AFP, CSCs, CTA, GEO, HCC, MAGE
34  2018 iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway. HCC, iNOS
35  2018 Low-level shear stress promotes migration of liver cancer stem cells via the FAK-ERK1/2 signalling pathway. AFM, CSCs, FAK
36  2018 MicroRNA regulation of liver cancer stem cells. CSCs, EMT, miRNAs
37  2018 MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis. HCC, miRNA, OS, PFS
38  2018 MiR-2861 Behaves as a Biomarker of Lung Cancer Stem Cells and Regulates the HDAC5-ERK System Genes. CSCs
39  2018 MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6. CSCs
40  2018 Role of YAP in lung cancer resistance to cisplatin. CDDP, YAP
41  2018 Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC. HCC
42  2018 Utilization of lung cancer cell lines for the study of lung cancer stem cells. FACS, MACS
43  2018 [Research Progress in the Therapeutic Strategy Based on Targeting at 
Lung Cancer Stem Cell]. ---
44  2017 beta-catenin inhibitors suppress cells proliferation and promote cells apoptosis in PC9 lung cancer stem cells. PP
45  2017 Chemoresistant lung cancer stem cells display high DNA repair capability to remove cisplatin-induced DNA damage. dLCSCs
46  2017 Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance. LPC
47  2017 Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. HCC, lncRNAs
48  2017 Effects of quantum dots on the ROS amount of liver cancer stem cells. BSA, LC, PEG, QDs, ROS
49  2017 ELK3 promotes the migration and invasion of liver cancer stem cells by targeting HIF-1alpha. CSCs, ERK, HCC, HIF-1alpha
50  2017 FGF1 and IGF1-conditioned 3D culture system promoted the amplification and cancer stemness of lung cancer cells. ---
51  2017 Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells. ALDH, IL-6, NSCLC
52  2017 Kruppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/beta-catenin signaling. HCC, KLF8
53  2017 Long noncoding RNA in liver cancer stem cells. CSCs, HCC
54  2017 Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway. CSC, FAK
55  2017 Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133. GEMs, HCC
56  2017 Tg737 acts as a key driver of invasion and migration in liver cancer stem cells and correlates with poor prognosis in patients with hepatocellular carcinoma. AFP, AJCC, HCC, MMP-2, SP
57  2017 The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. CSCs
58  2016 Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. CQ, SAL, SCNL
59  2016 Combination of 5-fluorouracil and 2-morphilino-8-phenyl-4H-chromen-4-one may inhibit liver cancer stem cell activity. 5-FU
60  2016 Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes. TMs
61  2016 Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. cDNA, DEGs, EMT, ESCs, qRT-PCR
62  2016 Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. CSCs, HCC, PTEN, TNF
63  2016 Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. IL-6, lncRNAs
64  2016 MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. ERK
65  2016 Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. M2-TAMs, TAMs
66  2016 Notch and Wnt/beta-catenin signaling pathway play important roles in activating liver cancer stem cells. HCC
67  2016 Overexpression of microRNA-21 strengthens stem cell-like characteristics in a hepatocellular carcinoma cell line. miR-21
68  2016 Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling. NSCLC
69  2016 Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line. BrMC, HCC, LCSLCs, SFCs
70  2016 The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. HCC
71  2016 Tumorigenesis of smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is related to its ability to stimulate thromboxane synthase and enhance stemness of non-small cell lung cancer stem cells. TXS
72  2015 Enhancing HOTAIR/MiR-10b Drives Normal Liver Stem Cells Toward a Tendency to Malignant Transformation Through Inducing Epithelial- to-Mesenchymal Transition. CSC, EMT, HOTAIR, LNSCs, ncRNAs
73  2015 Identification of cancer stem cell subpopulations of CD34(+) PLC/PRF/5 that result in three types of human liver carcinomas. CC, CHCs, HCCs, HLCs, TICs
74  2015 Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells. EMT, HCC, SP
75  2015 Regulation of miRNAs affects radiobiological response of lung cancer stem cells. CSCs, miRNAs, RT
76  2015 Research progress and prospects of markers for liver cancer stem cells. CSC
77  2015 Short hairpin RNA targeting AKT1 and PI3K/p85 suppresses the proliferation and self-renewal of lung cancer stem cells. PCNA, PI3K, sh
78  2015 Targeting cancer stem cells as a therapeutic approach in liver cancer. CSCs, HCC
79  2015 Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. ADC, EGFR, EGFRtyr1068, NSCLC, SCC, TKIs, WT
80  2015 Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells. CSCs, EMT, HCC, NF-kappaB, UTMD
81  2015 Wnt blockers inhibit the proliferation of lung cancer stem cells. PP
82  2015 Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells. CSCs
83  2014 Casticin inhibits epithelial-mesenchymal transition of liver cancer stem cells of the SMMC-7721 cell line through downregulating Twist. CSCs, EMT, SFCs
84  2014 Casticin inhibits self-renewal of liver cancer stem cells from the MHCC97 cell line. HCC
85  2014 Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. NSCLC
86  2014 Flow cytometric analysis of CD133- and EpCAM-positive cells in the peripheral blood of patients with lung cancer. ---
87  2014 Liver cancer stem cells are selectively enriched by low-dose cisplatin. ALDH1
88  2013 8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling. BrMC, EMT, HCC, SFCs
89  2013 8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of beta-catenin. BrMC, EMT, SFCs
90  2013 Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. CQ, HCC
91  2013 CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. CSCs, HCC, shRNA
92  2013 Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review). CSC, EpCAM, HCC, TGF-beta
93  2013 Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. CSC, HCCs
94  2013 Upregulated microRNA-92b regulates the differentiation and proliferation of EpCAM-positive fetal liver cells by targeting C/EBPss. miRNAs
95  2013 [Novel therapeutic strategies for treatment of hepatocellular carcinoma: targeting intervention on liver cancer stem cells]. CSCs, HCC
96  2010 MicroRNAs involved in neoplastic transformation of liver cancer stem cells. DEN, HCC, miRNA, RT-PCR, SP